Sesame Summit 2026 – application open

OutPost Bio Raises €2.9M Pre-Seed to Make Human Microbiology Computable

The human microbiome — the vast community of microorganisms colonising the gut, skin, and other organs — has long been recognised as a critical but poorly understood variable in human health. Despite its influence on how drugs are metabolised, how pathogens spread, and how the body responds to treatment, the microbiome has remained computationally intractable. That gap is what London-based OutPost Bio is setting out to close.

The biotech startup has raised €2.9 million (approximately $3.5 million) in a pre-seed funding round to accelerate its platform for making human microbiology computable at scale. The round was co-led by Merantix Capital and Seedcamp, with participation from OpenSeed VC, Defined, and a group of strategic family offices and angel investors.

A Closed Loop Between the Lab and the Algorithm

At the heart of OutPost Bio’s approach is what it calls the Lab-in-the-Loop platform — a system that integrates automated experimentation with machine learning in a continuous feedback cycle. Rather than treating laboratory work and modelling as sequential activities, the platform routes insights from ML models directly back into the experimental design, accelerating the generation of functional biological data.

The result is a proprietary dataset of human-derived microbial interactions that, the company argues, goes far beyond the correlational evidence available in existing literature. Microbial communities can dramatically alter drugs and other interventions, yet this layer has been largely ignored because the data has not existed at scale. For the first time, the platform aims to move beyond correlations to reveal causal pathways.

For pharmaceutical and biotech partners, this translates into a concrete set of applications: predicting microbe-mediated drug metabolism, identifying potential toxicity signals earlier in development, and building the regulatory evidence needed to bring safer formulations to market.

The Team Behind the Science

OutPost Bio was founded in 2025 by Dr Jenny Yang and Alex Merwin. Dr Yang — an Oxford PhD and former Marie Curie Fellow with a background in clinical machine learning — serves as CEO, bringing a rare combination of bench science expertise and applied AI experience to the role. Merwin, the company’s COO, previously led growth for health and bio startups at Amazon Web Services.

The founding team is further strengthened by Dr Heidi Arjes (VP of R&D, with two decades of microbiology experience across academia and industry), Dr Saif Ur-Rehman (Director of Data Engineering, formerly a founding engineer at Basecamp Research), and Dr Neythen Treloar (Principal ML Scientist, with expertise in microbial foundation models).

Investor Confidence in a Fast-Growing Market

The round reflects growing investor interest in precision microbiome science. Europe’s human microbiome market was valued at approximately $290 million in 2025 and is forecast to reach $1.31 billion by 2031, advancing at a compound annual rate of 28.6%. European research institutions conducted more than 820 microbiome-based clinical studies in 2025, led by Germany, the United Kingdom, and France.

Merantix Capital — a Berlin-based deep tech venture fund focused on AI-driven life sciences — and Seedcamp, one of Europe’s most prolific seed investors, co-leading the round positions OutPost Bio at the intersection of two investable themes: AI-accelerated drug discovery and the microbiome’s mounting clinical relevance. Additional backing from OpenSeed VC and Defined brings further domain expertise in biotech and digital health.

The pre-seed capital will be deployed to expand the Lab-in-the-Loop platform, scale proprietary data generation, and deepen partnerships with pharmaceutical companies seeking to integrate microbial modelling into their development pipelines.

Redefining Microbiology as a Computational Layer

The implications for pharmaceutical R&D are significant. Historically, the microbiome has been treated as a confounding variable rather than a predictable parameter. If OutPost Bio can deliver consistent, causal models of microbial behaviour, the practical benefit for drug developers is earlier and less costly de-risking of clinical candidates — particularly in areas such as oral drug metabolism, gut-delivered therapeutics, and microbiome-targeted interventions.

The company’s dual presence in London and Boston also positions it well to serve European and US pharma markets simultaneously, giving partners on both sides of the Atlantic access to the platform’s data and modelling capabilities.

DetailInformation
CompanyOutPost Bio
Founded2025
HQLondon, UK / Boston, USA
RoundPre-seed
Amount€2.9M ($3.5M)
Lead InvestorsMerantix Capital, Seedcamp
Other InvestorsOpenSeed VC, Defined, family offices & angels
TechnologyLab-in-the-Loop platform
FocusMaking human microbiology computable

you might also like

Fundraising 3 hours ago

London-based AI laboratory Ineffable Intelligence has emerged from stealth with a $1.1 billion seed round at a $5.1 billion post-money valuation, the company confirmed on 27 April 2026. The financing is the largest seed round ever raised by a European company and one of the largest first-money-in rounds in the global history of artificial intelligence. The round was co-led by Sequoia Capital and Lightspeed Venture Partners. Participating investors included Nvidia, DST Global, Index Ventures, Google, and the UK Sovereign AI Fund, the British government’s recently established vehicle for backing strategic AI capacity on home soil. A bet on a different path to general intelligence Ineffable Intelligence was founded in 2025 by David Silver, the former Vice President of Reinforcement Learning at Google DeepMind and the principal architect of AlphaGo, AlphaZero and AlphaStar. He is joined by three further DeepMind alumni: Wojciech Czarnecki, Lasse Espeholt and Junhyuk Oh. All four have spent the past decade at the frontier of reinforcement learning research, the discipline behind some of the most consequential demonstrations of machine learning over the past ten years. The company describes its objective as building a “superlearner” — an AI system capable of acquiring knowledge directly from its own experience rather than from human-generated text or imagery. “Our mission is to make first contact with superintelligence,” Silver said in a statement accompanying the launch. “We are creating a superlearner that discovers all knowledge from its own experience, from elementary motor skills through to profound intellectual breakthroughs.” The framing is a deliberate departure from the dominant industry trajectory. Most leading AI laboratories, including OpenAI, Anthropic and Google DeepMind itself, have built large language models trained primarily on the corpus of the internet, then refined that training with human feedback. Ineffable’s wager is that the marginal returns on scaling text-based pretraining are diminishing and that the next leap in capability will come from agents that learn endlessly from the consequences of their own actions, in much the same way AlphaZero learnt the game of Go without studying any human matches. Why $1.1 billion at seed The size of the round is unusual even by the inflated standards of the 2026 AI capital cycle. Two factors appear to explain it. First, frontier reinforcement learning at the scale Ineffable describes is computationally extraordinarily expensive: the company will need to operate vast simulation environments and train very large models against them, an undertaking that consumes capital at a rate closer to physical R&D than to traditional software. Second, the round signals a strategic move by Europe’s investor and policy ecosystems to retain the most ambitious AI researchers on the continent. The presence of the UK Sovereign AI Fund alongside Sequoia, Lightspeed and Nvidia is the clearest expression of that intent. The British government has publicly framed the investment as a bet on breakthrough AI that “can discover new knowledge”, positioning the country as a willing co-investor in domestic frontier laboratories. For Ineffable, the implication is access not only to capital but to compute, regulatory engagement and the still-resilient academic talent base around UCL, Oxford, Cambridge and Imperial. Founder pledge of historic scale Alongside the funding announcement, Silver disclosed that he is committing 100 per cent of any personal proceeds from his Ineffable equity to charity via the Founders Pledge network — described by the organisation as the largest pledge in its history. At the round’s $5.1 billion valuation, that commitment could ultimately exceed several billion dollars if the company succeeds. It is a meaningful gesture in a sector where the reputational stakes around concentrated AI wealth are escalating, and one likely to be referenced in subsequent founder-led commitments. Implications for the European AI landscape Ineffable’s emergence reshapes the European AI map in three concrete ways. It establishes London as the home of the continent’s largest-ever seed-stage company, complicating Paris’s recent narrative of frontier-AI primacy after Mistral’s earlier rounds. It validates a thesis — that reinforcement learning, not transformer scaling, is the next frontier — that has lately been losing capital share to language-model incumbents. And it confirms that the UK government is now willing to act as a balance-sheet co-investor in domestic AI laboratories, a posture much closer to the French model than to the predominantly grant-based regimes elsewhere in Europe. The execution risk is non-trivial. Reinforcement learning at frontier scale has historically required years of careful environment design before producing competitive systems, and Ineffable’s “first contact” framing sets a high bar against which it will be judged. But for now, with a billion dollars on the balance sheet, four of the discipline’s most accomplished researchers in the founding team and a sovereign co-investor at its back, Ineffable Intelligence is the most heavily resourced new entrant in the European AI cycle. Sesamers covers European fundraising rounds across deeptech, fintech and AI. Source: tech.eu.

Fundraising 5 days ago

Belfast's Cloudsmith has raised $72M Series C led by TCV, with Insight Partners participating, to expand its artifact management platform and secure the AI-era software supply chain.

Fundraising 5 days ago

Berlin’s VREY has raised €3.3M seed led by Rubio Impact Ventures to roll out rooftop solar software for Germany’s multi-family buildings.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.